Distribution and elimination of protein therapeutics: A review
It was 1980s when the first therapeutic protein was launched in the market. It was recombinant DNAderived insulin. Since its inception, within the worldwide pharmaceutical sector, protein therapeutics has been enjoying the fastest growth, notably for the last few years. As a result it is assumed that the treatment methodology with the conventional drug therapy will be shifted towards therapeutic proteins in near future. It made revolution in the treatment of chronic diseases like cancer, diabetes, cardiovascular diseases. The major segments in protein therapeutics are monoclonal antibody, insulin, granulocyte-colony stimulating factor (G-CSF), coagulation factors etc. In this review paper we will discuss the general aspects of protein therapeutics with their advantages over small-molecule drugs, functional classification of therapeutic proteins and their uses. The pharmacokinetics of protein therapeutics, especially from the distribution and elimination characteristics of therapeutic proteins will be discussed in brief with relevant examples. The major challenges and future perspectives will also be presented in short.
S. J. Pharm. Sci. 4(2) 2011: 01-12
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.